- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Fischer sales rise, red ink drops
Fischer Imaging may be pulling itself out of the doldrums. The Denver company on April 21 released results for its first quarter (end-March) that indicated an 11% increase in revenues and a sharp drop in the vendor's net loss. Fischer reported that
Fischer Imaging may be pulling itself out of the doldrums. The Denver company on April 21 released results for its first quarter (end-March) that indicated an 11% increase in revenues and a sharp drop in the vendor's net loss. Fischer reported that orders are increasing for its Mammotest breast biopsy table, and the firm's backlog is at a record level.
For the quarter, Fischer reported revenues of $13.7 million, compared with sales of $12.3 million in the same period the year before. Fischer's net loss was $1.1 million in the first quarter, compared with a net loss of $3.9 million in the first quarter of 1996.
Mammotest orders were driven by Fischer's new relationship with Johnson & Johnson's Ethicon Endo-Surgery division, with whom Fischer signed an OEM alliance in October (SCAN 10/29/97). In addition, Fischer expects to be able to file a 510(k) for its SenoScan full-view digital mammography system by June or July.
Another mammography-related project in the works at Fischer is a breast biopsy device designed to work with 1.5-tesla Signa MRI scanners manufactured by GE Medical Systems of Milwaukee. Fischer is working on the project with MR mammography researcher Dr. Steven Harms, director of MRI at the University of Arkansas in Little Rock. The device is still in investigational review, and Fischer plans to discuss with Harms the timetable for the release of a commercial product.
Can Portable Dual-Energy X-Ray be a Viable Alternative to CT in the ICU?
September 13th 2024The use of a portable dual-energy X-ray detector in the ICU at one community hospital reportedly facilitated a 37.5 percent decrease in chest CT exams in comparison to the previous three months, according to research presented at the American Society of Emergency Radiology (ASER) meeting in Washington, D.C.
New Meta-Analysis Examines MRI Assessment for Treatment of Esophageal Cancer
September 12th 2024Diffusion-weighted MRI provided pooled sensitivity and specificity rates of 82 percent and 81 percent respectively for gauging patient response to concurrent chemoradiotherapy for esophageal cancer, according to new meta-analysis.
Study for Emerging PET/CT Agent Reveals ‘New Standard’ for Detecting Clear Cell Renal Cell Carcinoma
September 11th 2024Results from a multicenter phase 3 trial showed that the PET/CT imaging agent (89Zr)Zr-girentuximab had an 85.5 percent mean sensitivity rate for the diagnosis of clear cell renal cell carcinoma.
Can Radiomics and Autoencoders Enhance Real-Time Ultrasound Detection of Breast Cancer?
September 10th 2024Developed with breast ultrasound data from nearly 1,200 women, a model with mixed radiomic and autoencoder features had a 90 percent AUC for diagnosing breast cancer, according to new research.
